The genetic basis of kidney cancer: Implications for management and use of targeted therapeutic approaches

European Urology

Volumn 61, Issue 5, 2012, Pages 896-898

  Linehan, W Marston ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; ESTRONE; EVEROLIMUS; FUMARATE HYDRATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POLYBOMO 1 PROTEIN; SCATTER FACTOR RECEPTOR; SORAFENIB; SUCCINATE DEHYDROGENASE; SUNITINIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EB; TUBUROUS SCLEROSIS 1 PROTEIN; TUBUROUS SCLEROSIS 2 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

CANCER CHEMOTHERAPY; CANCER GROWTH; DRUG EFFICACY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; KIDNEY CANCER; PRIORITY JOURNAL; REVIEW;

EID: 84859435370     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.02.022     Document Type: Editorial

References (11)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer 127 2010 2893 2917
2. W.M. Linehan, M.M. Walther, and B. Zbar The genetic basis of cancer of the kidney J Urol 170 2003 2163 2172 (Pubitemid 37413950)
3. W.M. Linehan, R. Srinivasan, and L.S. Schmidt The genetic basis of kidney cancer: a metabolic disease Nature Rev Urol 7 2010 277 285
4. F. Latif, K. Tory, and J.R. Gnarra Identification of the von Hippel-Lindau disease tumor suppressor gene Science 260 1993 1317 1320 (Pubitemid 23231974)
5. M.L. Nickerson, E. Jaeger, and Y. Shi Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors Clin Cancer Res 14 2008 4726 4734
6. I. Varela, P. Tarpey, and K. Raine Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma Nature 469 2011 539 542
7. N. Kroeger, D.B. Seligson, and T. Klatte Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma Eur Urol 61 2012 888 895
8. N. Kroeger, E.N. Rampersaud, and J.J. Patard Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation J Urol 187 2012 418 423
9. S. Chakraborty, S. Zawieja, W. Wang, D.C. Zawieja, and M. Muthuchamy Lymphatic system: a vital link between metabolic syndrome and inflammation Ann N Y Acad Sci 1207 Suppl 1 2010 E94 E102
10. W.H. Tong, C. Sourbier, and G. Kovtunovych The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases metabolic propensities and lowers cellular iron levels Cancer Cell 20 2011 315 327
11. Mullen AR, Wheaton WW, Jin ES, et al. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature. In press. doi:10.1038/nature10642.